Lin Wu

Dr. Lin Wu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SYShandong Yu
Shandong Yu
YCYanpeng Chu
Yanpeng Chu
GLGang Li
Gang Li
LRLu Ren
Lu Ren
QZQing Zhang
Qing Zhang
LWLin Wu
Lin Wu
Background: Cataracts are the main cause of poor vision and blindness worldwide. The effects of statin administration on cataracts remain debated. Therefore, we conducted a systematic review and meta‐analysis to determine whether statin use affects the risk of cataracts. Methods and Results: We performed a systematic search of the electronic databases PubMed, EMBASE , and the Cochrane Library through January 2016. Weighted averages were reported as relative risk values with 95% CI s. Statistical heterogeneity scores were assessed with the standard Cochran's Q test and the I 2 statistic. A total of 6 cohort studies, 6 case–control studies, and 5 randomized controlled trials, together involving more than 313 200 patients, were included in our study. The pooled estimates of cohort studies indicated that the use of statins moderately increases the risk of cataracts (relative risk, 1.13; 95% CI , 1.01–1.25). The pooled estimates of case–control studies (relative risk=1.10, 95% CI , 0.99–1.23) and randomized controlled trials (relative risk, 0.89; 95% CI , 0.72–1.10) indicated that the use of statins does not increase the risk of cataracts. The sensitivity analysis confirmed the stability of the results. Heterogeneity was found among the cohort and case–control studies. Conclusions: Based on the present meta‐analysis of these studies, we could only conclude that there is no clear evidence showing that statin use increases the risk of cataracts. The most likely case is that there is no association between statin use and cataracts. Because of the considerable benefits of statins in cardiovascular patients, this issue should not deter their use.

10 November 2017 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Closed access
PDF file
SYShandong Yu
Shandong Yu
GLGang Li
Gang Li
CHChristopher L.-H. Huang
Christopher L.-H. Huang
MLMing Lei
Ming Lei
LWLin Wu
Lin Wu

4 August 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
GLGang Li
Gang Li
RWRyan L. Woltz
Ryan L. Woltz
CWCheng-Yu Wang
Cheng-Yu Wang
LRLu Ren
Lu Ren
PHPei-Xin He
Pei-Xin He
LWLin Wu
Lin Wu
Background: Long QT syndrome 3 (LQT3) is caused by SCN5A mutations. Late sodium current (late INa) inhibitors are current-specific to treat patients with LQT3, but the mechanisms underlying mexiletine (MEX)-sensitive (N1325S and R1623Q) and insensitive (M1652R) mutations remains to be elucidated. Methods: LQT3 patients with causative mutations were treated with oral MEX following i.v. lidocaine. Whole-cell patch-clamp techniques and molecular remodeling were used to determine the mechanisms underlying the sensitivity to MEX. Results: Intravenous administration of lidocaine followed by MEX orally in LQT patients with N1325S and R1623Q sodium channel mutation shortened QTc interval, abolished arrhythmias and completely normalized the ECG. In HEK293 cells, the steady-state inactivation curves of the M1652R channels were rightward shifted by 5.6 mV relative to the WT channel. In contrast, the R1623Q mutation caused a leftward shift of the steady-state inactivation curve by 15.2 mV compared with WT channel, and N1325S mutation did not affect steady-state inactivation (n = 5-13, P < 0.05). The extent of the window current was expanded in all three mutant channels compared with WT. All three mutations increased late INa with the greatest amplitude in the M1652R channel (n=9-15, P<0.05). MEX caused a hyperpolarizing shift of the steady-state inactivation and delayed the recovery of all three mutant channels. Furthermore, it suppressed late INa in N1325S and R1623Q to a greater extent compared to that of M1652R mutant channel. Mutations altered the sensitivity of Nav1.5 to MEX through allosteric mechanisms, by changing the conformation of Nav1.5 to become more or less favorable for MEX binding. Late INa inhibitors suppressed late INa in N1325S and R1623Q to a greater extent than that in the M1652R mutation (n =4-7,P < 0.05). Conclusion: The N1325S, R1623Q and M1652R mutations is associated with a variable augmentation of late INa, which was reversed by MEX. M1652R mutation changes the conformation of Nav1.5 that disrupt the inactivation of channel affecting MEX binding, corresponding to the poor response to MEX. The lidocaine test, molecular modeling and drugs screening in cells expressing mutant channels are useful for predicting the effectiveness of late INa inhibitors.

20 April 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XWXiao-Hong Wei
Xiao-Hong Wei
SYShan-Dong Yu
Shan-Dong Yu
LRLu Ren
Lu Ren
SHSi-Hui Huang
Si-Hui Huang
QYQiao-Mei Yang
Qiao-Mei Yang
LWLin Wu
Lin Wu
Cardiac arrhythmias associated with intracellular calcium inhomeostasis are refractory to antiarrhythmic therapy. We hypothesized that late sodium current (INa) contributed to the calcium-related arrhythmias. Monophasic action potential duration at 90% completion of repolarization (MAPD90) was significantly increased and ventricular arrhythmias were observed in hearts with increased intracellular calcium concentration ([Ca2+]i) by using Bay K 8644, and the increase became greater in hearts treated with a combination of ATX-II and Bay K 8644 compared to Bay K 8644 alone. The prolongations caused by Bay K 8644 and frequent episodes of ventricular tachycardias, both in absence and presence of ATX-II, were significantly attenuated or abolished by late INa inhibitors TTX and eleclazine. In rabbit ventricular myocytes, Bay K 8644 increased ICaL density, calcium transient and myocyte contraction. TTX and eleclazine decreased the amplitude of late INa, the reverse use dependence of MAPD90 at slower heart rate, and attenuated the increase of intracellular calcium transient and myocyte contraction. TTX diminished the phosphorylation of CaMKII-δ and Nav 1.5 in hearts treated with Bay K 8644 and ATX-II. In conclusion, late INa contributes to ventricular arrhythmias and its inhibition is plausible to treat arrhythmias in hearts with increased [Ca2+]i

13 March 2025 in Annals of Medicine
Verified
Journal Article
Open access
LZLifan Zhang
Lifan Zhang
BLBingxun Li
Bingxun Li
LWLin Wu
Lin Wu
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia characterized by consistently irregular atrial and ventricular contractions. Heart rate variability (HRV) refers to the changes in the intervals between consecutive ventricular heartbeats. In sinus rhythm, HRV may be subtle and is quantitatively reflecting the dynamic interplay of the cardiac autonomic nervous system, which plays a crucial role in the onset, development, and maintenance of AF. HRV metrics, consisting of time-domain, frequency-domain, and nonlinear parameters, have been verified to vary significantly before and after AF episodes, and AF treatment-related procedures such as electrical cardioversion, ablation, and surgery of AF. Therefore, HRV may serve as a digital biomarker in predicting AF risk in long-term and acute risk period, identification of patients with AF risk in sinus rhythm and recurrence risk stratification after procedures. HRV in AF rhythm, predominantly influenced by dynamic atrioventricular node conduction under the onslaught of irregular atrial impulses, shows a huge disparity compared to that in sinus rhythm. Despite this, HRV in AF rhythm still provides valuable prognostic information, as reduced HRV may indicate a poor heart function and outcomes in patients with AF. Despite being influenced by lots of variables, HRV can still serve as an independent digital biomarker in the clinical management of AF throughout its entire lifecycle.

1 July 2019 in Heart Rhythm
Verified
Journal Article
Closed access
QZQing Zhang
Qing Zhang
JMJi-Hua Ma
Ji-Hua Ma
HLHong Li
Hong Li
XWXiao-Hong Wei
Xiao-Hong Wei
JZJie Zheng
Jie Zheng
LWLin Wu
Lin Wu